Company and product development timeline
Company Founded
AMLo Biosciences Ltd is founded in Newcastle-upon-Tyne, UK, as a spin-out business from Newcastle University
Summer
2017
Autumn
2017
Investment–UKRI: £218k
AMLo is awarded start-up funds by Innovate UK, part of UK Research & Innovation
NICE
AMLo wins the inaugural National Institute for Health and Care Excellence (NICE) AdviSeMe Prize for its AMBLor prognostic test
Winter
2017
Spring
2018
Investment–NIHR: £1.2m
The National Institute of Health Research makes a major investment in AMLo
AMBLor Trademarked
AMBLor is successfully trademarked via UK’s Intellectual Property Office (IPO)
Autumn
2018
Winter
2018
Investment–Private Equity: <£1m
Growing confidence in AMLo’s research nets PE funding of close to £1 million
Patent: Europe
“Biomarkers for disease progression in melanoma”: Patent granted, 2 January 2019
January
2019
Spring
2020
Paper: Validation cohort n=379 publication (Ellis)
Paper describing the potential of AMBRA1 and loricrin as prognostic biomarkers for early stage melanoma in a discovery cohort of 379 retrospective tumour biopsies
Patent: United States of America
“Biomarkers for disease progression in melanoma”: Patent granted, 28 April 2020
April
2020
August
2020
Patent: Australia
“Biomarkers for disease progression in melanoma”: Patent granted, 20 August 2020
Investment–Private Equity: £1.5m
AMLo secures PE funding totalling £1.5 million from the North East Innovation Fund, Esperante Ventures and the British Innovation Fund
Winter
2020
Winter
2021
Poster: AMBLor cohort n=411 publication (Ewen)
Poster presented at Society for Melanoma Research (SMR) 2021 Congress describing evaluation of AMBLor as prognostic biomarkers for early stage melanoma in a validation cohort of 411 retrospective tumour biopsies
Paper: Cosgarea
(2021 ePub in BR J Dermatol)
Paper describing the mechanism by which AMBRA1 and loricrin are lost in the peritumour environment surrounding primary melanoma tumours causing breakdown of the structural integrity of the epidermis
Winter
2021
Spring
2022
Referral Service
Launch of UK referral service for AMBRA1 and loricrin testing
Investment–Private Equity: £2.4m
AMLo secures new PE funding from Ascension’s Life Fund and Conduit’s EIS Impact Fund, and re-investment from NorthStar Ventures, Future Planet Capital’s BIF Opportunities Fund, Esperante, and a number of Angel Investors
April
2022
May
2022
UK NICE Advice
The UK’s national body publishes its advice on AMBLor stating cost savings gained as a result of future changes to management pathways using AMBLor
AMBLor US launch
AMLo’s technology is commercially available in the US as the AMBLor® Laboratory-Developed Test
February
2023
October
2023
Innovate UK Investor Partnership
AMLo Biosciences receives a grant award of £304k
Interim funding of £1.5m
November
2023
Summer
2017
Company Founded
AMLo Biosciences Ltd is founded in Newcastle-upon-Tyne, UK, as a spin-out business from Newcastle University
Autumn
2017
Investment–UKRI: £218,000
AMLo is awarded start-up funds by Innovate UK, part of UK Research & Innovation
Winter
2017
NICE
AMLo wins the inaugural National Institute for Health and Care Excellence (NICE) AdviSeMe Prize for its AMBLor prognostic test
Spring
2018
Investment–NIHR: £1.2 million
The National Institute of Health Research makes a major investment in AMLo
Autumn
2018
AMBLor Trademarked
AMBLor is successfully trademarked via UK’s Intellectual Property Office (IPO)
Winter
2018
Investment–Private Equity: <£1 million
Growing confidence in AMLo’s research nets PE funding of close to £1 million
January
2019
Patent: Europe
“Biomarkers for disease progression in melanoma”: Patent granted, 2 January 2019
Spring
2020
Paper: Validation cohort n=379 publication (Ellis)
Paper describing the potential of AMBRA1 and loricrin as prognostic biomarkers for early stage melanoma in a discovery cohort of 379 retrospective tumour biopsies
April
2020
Patent: United States of America
“Biomarkers for disease progression in melanoma”: Patent granted, 28 April 2020
August
2020
Patent: Australia
“Biomarkers for disease progression in melanoma”: Patent granted, 20 August 2020
Winter
2020
Investment–Private Equity: £1.5 million
AMLo secures PE funding totalling £1.5 million from the North East Innovation Fund, Esperante Ventures and the British Innovation Fund
Winter
2021
Poster: AMBLor cohort n=411 publication (Ewen)
Poster presented at Society for Melanoma Research (SMR) 2021 Congress describing evaluation of AMBLor as prognostic biomarkers for early stage melanoma in a validation cohort of 411 retrospective tumour biopsies
Winter
2021
Paper: Cosgarea
(2021 ePub in Br J Dermatol)
Paper describing the mechanism by which AMBRA1 and loricrin are lost in the peritumour environment surrounding primary melanoma tumours causing breakdown of the structural integrity of the epidermis
Spring
2022
Referral Service
Launch of UK referral service for AMBRA1 and loricrin testing
April
2022
Investment–Private Equity: £2.4m
AMLo secures new PE funding from Ascension’s Life Fund and Conduit’s EIS Impact Fund, and re-investment from NorthStar Ventures, Future Planet Capital’s BIF Opportunities Fund, Esperante, and a number of Angel Investors
May
2022
UK NICE Advice
The UK’s national body publishes its advice on AMBLor stating cost savings gained as a result of future changes to management pathways using AMBLor
February
2023
AMBLor US launch
AMLo’s technology is commercially available in the US as the AMBLor® Laboratory-Developed Test
October
2023
Innovate UK Investor Partnership
AMLo Biosciences receives a grant award of £304k
November
2023
Interim funding of £1.5m
Job code: 2023/AMBLor/UK/0186
Date of preparation: January 2024
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address (Visitors and Deliveries): Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX ///wider.admire.guard
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter